Alnylam Pharmace. buy Jefferies Financial Group Inc.
Start price
07.07.25
/
50%
€273.90
Target price
07.07.26
€326.17
Performance (%)
23.44%
Price
23.12.25
€338.10
Summary
This prediction is currently active. The prediction currently has a performance of 23.44%. This prediction currently runs until 07.07.26. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 1.593% | 1.593% |
| iShares Core DAX® | 0.765% | 4.791% |
| iShares Nasdaq 100 | 1.418% | 3.133% |
| iShares Nikkei 225® | 0.658% | 0.972% |
| iShares S&P 500 | 1.310% | 2.279% |
Comments by Jefferies_Financial_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Jefferies Financial Group Inc. from $328.00 to $384.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Jefferies_Financial_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€389.00
30.10.25
30.10.25
€472.69
30.10.26
30.10.26
-13.08%
23.12.25
23.12.25
